芪苈强心胶囊治疗慢性心力衰竭的安全性及有效性的系统评价  

Safety and efficacy of Qiliqiangxin capsule on chronic heart failure

作　　者：何穗智[1] 刘素芳[1] 吴伟康[2] 许顶立[3] 

机构地区：[1]中山大学公共卫生学院预防医学研究所医学统计与流行病学系,广州510080 [2]中山大学中西医结合研究所 [3]南方医科大学南方医院

出　　处：《临床心血管病杂志》2013年第8期605-608,共4页Journal of Clinical Cardiology

摘　　要：目的:评价芪苈强心胶囊治疗慢性心力衰竭(CHF)的安全性及有效性。方法:纳入42项随机对照试验,包括4 490例CHF患者。采用RevMan 5.1软件进行Meta分析。结果:常规治疗+芪苈强心胶囊组较常规组降低了再住院率(OR=0.37,95%CI:0.22～0.61,P=0.0001)、复发率(OR=0.24,95%CI:0.11～0.56,P=0.0008)及常见不良反应率(OR=0.41,95%CI:0.17～0.96,P=0.04),有降低死亡率的趋势(OR=0.33,95%CI:0.20～1.03,P=0.06);34篇论文报道未发现芪苈强心胶囊有明显不良作用。结论:芪苈强心胶囊治疗CHF的复发率较低,中短期疗效显著,安全性好,但长期安全性和疗效有待进一步验证。Objective：To evaluate the safety and clinical efficacy of Qiliqiangxin capsule in chronic heart failure （CHF）. Method：Forty two randomized controlled trials （RCTs） were evaluated and analyzed by the software RevMan 5.1. The RCTs include 4 490 patients with CHF. Result：Compared with placebo group, the readmission rate （OR=0.37, 95%CI：0.22-0.61, P=0.0001）, the recurrence rate （OR：0.24, 95%CI：0.11-0.56, P=0.0008） and the adverse reaction rate （OR=0.41, 95 % CI：0.17-0.96, P=0.04） in Qiliqiangxin group all were decreased, and the mortality showed decreased trends （OR=0.33, 95%CI：0.20-1.03 , P=0.06）. Thirty-four papers reported that there were no obvious toxic and side effects about Qiliqiangxin capsules. Conclusion：Qiliqiangxin capsule is safe for CHF, but it also need further studies to provide more sufficient evidences for the long term safety.

关 键 词：心力衰竭 芪苈强心胶囊 安全性 随机对照试验 

分 类 号：R541.6[医药卫生—心血管疾病]